Prognostic value of upar forms in colon and breast cancer

Informazioni relative al progetto

TIMO PIIRONEN

ID dell’accordo di sovvenzione: QLK4-CT-1999-51464

Progetto chiuso

Data di avvio 1 Agosto 2000

Data di completamento 31 Luglio 2002

Finanziato da

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Costo totale € 143 952,00

Contributo UE € 143 952,00

Coordinato da

COPENHAGEN UNIVERSITY HOSPITAL
Denmark

Obiettivo

Investigation of the clinical prognostic value of soluble urokinase plasminogen activator receptor (uPAR) forms in blood and tissue extracts from patients with colon and breast cancer, aiming to develop new methods which will aid in the decision-making needed in the management of cancer patients.

Campo scientifico

• medical and health sciences › clinical medicine › oncology › breast cancer

Programma(i)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Argomento(i)

• 1.1.1.-4. - Key action Environment and Health

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

RGI - Research grants (individual fellowships)

Coordinatore

COPENHAGEN UNIVERSITY HOSPITAL

• Contributo UE: Nessun dato
• Indirizzo: Stransboulevarden 49 ; 2100 KOEPENHAGEN ; Danimarca
• Costo totale: Nessun dato